title: Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III.
abstract: To determine whether 2 monovalent group B streptococcus (GBS) serotype II or III capsular polysaccharide (CPS)-tetanus toxoid (TT) conjugate vaccines combined in a single intramuscular dose would elicit immune responses comparable to those of monovalent vaccines, 75 healthy adults were randomized to receive GBS II-TT (3.6 micro g of CPS), GBS III-TT (12.5 micro g of CPS), or a bivalent mixture of GBS II-TT/III-TT vaccine (double-masked design). Vaccines were well tolerated. Four-fold or greater increases in GBS II or III CPS-specific IgG, respectively, were noted in postimmunization serum samples from 80%-90% of bivalent conjugate vaccine recipients, and these responses were similar to those of recipients of GBS II-TT or GBS III-TT monovalent vaccines. Immune serum samples promoted the opsonophagocytic killing of types II and III GBS in vitro. Unexpectedly, some recipients of these vaccines developed cross-reactive antibodies to the structurally similar heterologous polysaccharide. These results support the feasibility of a multivalent vaccine for the 5 prevalent invasive disease-causing GBS CPS serotypes.
authors.affiliation: Sections of Infectious Diseases, Department of Pediatrics, and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA. cbaker@bcm.tmc.edu
authors.forename: Carol J
authors.initials: CJ
authors.lastname: Baker
authors.forename: Marcia A
authors.initials: MA
authors.lastname: Rench
authors.forename: Marisol
authors.initials: M
authors.lastname: Fernandez
authors.forename: Lawrence C
authors.initials: LC
authors.lastname: Paoletti
authors.forename: Dennis L
authors.initials: DL
authors.lastname: Kasper
authors.forename: Morven S
authors.initials: MS
authors.lastname: Edwards
mesh_terms: D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D008297:Male; D008875:Middle Aged; D013290:Streptococcal Infections / Q000276:immunology* / Q000517:prevention & control; D022541:Streptococcal Vaccines / Q000009:adverse effects* / Q000276:immunology*; D013292:Streptococcus agalactiae / Q000276:immunology*; D018074:Vaccines, Conjugate / Q000009:adverse effects* / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D022541:Streptococcal Vaccines; D018074:Vaccines, Conjugate